These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 29469692)

  • 1. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
    Yao Y; Thomsen SF
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
    Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.
    Schlapbach C; Hänni T; Yawalkar N; Hunger RE
    J Am Acad Dermatol; 2011 Oct; 65(4):790-798. PubMed ID: 21641076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
    Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
    Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.
    Thomi R; Yerly D; Yawalkar N; Simon D; Schlapbach C; Hunger RE
    Br J Dermatol; 2017 Nov; 177(5):1358-1366. PubMed ID: 28301691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?
    Frew JW
    J Dermatolog Treat; 2020 Jun; 31(4):422-423. PubMed ID: 30945961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
    Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
    Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hidradenitis suppurativa and perianal Crohn disease: differential diagnosis.
    Bassas-Vila J; González Lama Y
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():27-31. PubMed ID: 28081767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
    Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
    Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.
    Fletcher JM; Moran B; Petrasca A; Smith CM
    Clin Exp Immunol; 2020 Aug; 201(2):121-134. PubMed ID: 32379344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two diseases one remedy? Systemic amyloidosis secondary to hidradenitis suppurativa: Treatment with infliximab.
    Özer İ; Karaçin C; Adışen E; Güz G; Ali Gürer M
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27862787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
    Theut Riis P; Thorlacius LR; Jemec GB
    Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
    van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
    Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Anticytokine Autoantibody Levels Are Not Increased in Hidradenitis Suppurativa: A Case-Control Pilot Study.
    Theut Riis P; von Stemann JH; Kjærsgaard Andersen R; Hansen MB; Jemec GBE
    Dermatology; 2017; 233(2-3):126-128. PubMed ID: 28675899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
    van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
    Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.
    Kelly G; Hughes R; McGarry T; van den Born M; Adamzik K; Fitzgerald R; Lawlor C; Tobin AM; Sweeney CM; Kirby B
    Br J Dermatol; 2015 Dec; 173(6):1431-9. PubMed ID: 26282467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
    Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
    J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-36 cytokines are increased in acne and hidradenitis suppurativa.
    Di Caprio R; Balato A; Caiazzo G; Lembo S; Raimondo A; Fabbrocini G; Monfrecola G
    Arch Dermatol Res; 2017 Oct; 309(8):673-678. PubMed ID: 28852851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.